Nanovibronix (NASDAQ:FEED) Upgraded at Wall Street Zen

Nanovibronix (NASDAQ:FEED) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Tuesday.

Separately, Weiss Ratings initiated coverage on shares of Nanovibronix in a research report on Tuesday, January 27th. They set a “sell (e+)” rating on the stock. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Nanovibronix Stock Performance

NASDAQ FEED opened at $1.31 on Tuesday. The business has a fifty day moving average price of $1.91. The company has a market cap of $4.85 million, a price-to-earnings ratio of -0.03 and a beta of 2.09. Nanovibronix has a 1 year low of $0.99 and a 1 year high of $51.20.

Nanovibronix (NASDAQ:FEED) last released its quarterly earnings results on Wednesday, April 15th. The company reported ($20.00) earnings per share for the quarter. Nanovibronix had a negative net margin of 712.30% and a negative return on equity of 47.82%. The firm had revenue of $0.31 million for the quarter.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.